Godavari Drugs

Which are the latest news on Godavari Drugs?

Why is Godavari Drugs Ltd falling/rising?

As of 18-Jul, Godavari Drugs Ltd's stock price is stable at 120.00, with a year-to-date increase of 56.19%. Despite recent declines, increased investor participation and outperformance against its sector indicate potential positive momentum.

As of 18-Jul, Godavari Drugs Ltd's stock price is currently stable at 120.00, showing no change (0.00%). Despite this stability, the stock has experienced a decline over the past week and month, with a decrease of 2.44% over the last week and 4.72% over the last month. However, it has performed well year-to-date, with an impressive increase of 56.19%, significantly outperforming the Sensex, which has fallen by 8.30% in the same period.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 1.41%, suggesting some positive momentum. Additionally, there has been a notable increase in investor participation, with a delivery volume of 2.43 k on 16 July, which is up by 42.94% compared to the 5-day average. This rising interest may contribute to a more favorable outlook for the stock.<BR><BR>In terms of moving averages, the stock is currently above the 100-day and 200-day moving averages, but below the 5-day, 20-day, and 50-day moving averages. This mixed performance in moving averages could indicate some volatility in the short term.<BR><BR>Overall, while Godavari Drugs Ltd is not currently rising in price, its strong year-to-date performance, increased investor participation, and outperformance against its sector suggest that there are positive factors at play that could influence future price movements.

Should I buy, sell or hold Godavari Drugs Ltd?

How big is Godavari Drugs?

As of 10th June, Godavari Drugs Ltd has a market capitalization of 127.00 Cr, with recent net sales of 105.80 Cr and a net profit of 4.09 Cr. The balance sheet for March 2025 shows shareholder's funds of 43.35 Cr and total assets of 143.08 Cr.

As of 10th June, Godavari Drugs Ltd has a market capitalization of 127.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Godavari Drugs reported Net Sales of 105.80 Cr and a Net Profit of 4.09 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 43.35 Cr and Total Assets of 143.08 Cr.

Who are in the management team of Godavari Drugs?

The management team of Godavari Drugs includes Mukund Kakani (Managing Director), Mohit Jaju (Whole Time Director & CFO), and several Non-Executive Directors, including S A Hussain, Ramesh Babu Telugu, Vimala B Madon, Ghanshyam Jaju (Chairman), and Mahindra Uday Bhalerao, along with Venkatesh Achanta as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Godavari Drugs includes the following key members:<BR><BR>1. **Mukund Kakani** - Managing Director<BR>2. **S A Hussain** - Non-Executive & Independent Director<BR>3. **Mohit Jaju** - Whole Time Director & CFO<BR>4. **Ramesh Babu Telugu** - Non-Executive & Independent Director<BR>5. **Vimala B Madon** - Non-Executive & Independent Director<BR>6. **Ghanshyam Jaju** - Chairman (Non-Executive)<BR>7. **Mahindra Uday Bhalerao** - Non-Executive Director<BR>8. **Venkatesh Achanta** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Godavari Drugs?

Godavari Drugs' peers include Smruthi Organic, Bal Pharma, Lactose (India), Tyche Industries, and others. In terms of management risk, growth, and capital structure, they vary, with Concord Drugs showing the highest 1-year return at 161.37%, while Godavari Drugs has a return of 24.25%.

Peers: The peers of Godavari Drugs are Smruthi Organic, Bal Pharma, Lactose (India), Tyche Industries, Concord Drugs, Denis Chem Lab, Pharmaids Pharma, Sotac Pharma, Balaxi Pharma, and Vaishali Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab, while Average management risk is found at Smruthi Organic, Bal Pharma, Tyche Industries, and Godavari Drugs. Below Average management risk is present at Lactose (India), Concord Drugs, Pharmaids Pharma, Sotac Pharma, Balaxi Pharma, and Vaishali Pharma. Growth is Excellent at Lactose (India), while Average growth is noted at Sotac Pharma, and Below Average growth is seen at Smruthi Organic, Bal Pharma, Tyche Industries, Godavari Drugs, Concord Drugs, Denis Chem Lab, Pharmaids Pharma, Balaxi Pharma, and Vaishali Pharma. Capital Structure is Good at Smruthi Organic, Excellent at Tyche Industries, Denis Chem Lab, and Balaxi Pharma, while Below Average capital structure is found at Bal Pharma, Lactose (India), Godavari Drugs, Concord Drugs, Pharmaids Pharma, and Vaishali Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Concord Drugs at 161.37%, while Pharmaids Pharma has the lowest at -52.99%. Godavari Drugs has a 1-year return of 24.25%, which is significantly higher than Pharmaids Pharma but lower than Concord Drugs. Additionally, the six-month return is negative for Denis Chem Lab, Pharmaids Pharma, and Vaishali Pharma.

What does Godavari Drugs do?

Godavari Drugs Ltd manufactures Active Pharmaceutical Ingredients (API) and drug intermediates in the Pharmaceuticals & Biotechnology industry, with a market cap of INR 127 Cr. As of March 2026, it reported net sales of 33 Cr and a net profit of 1 Cr.

Overview:<BR>Godavari Drugs Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in an unspecified year and has maintained its status as a manufacturer of pharmaceutical products. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 33 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 127 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 32.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.88 <BR>Return on Equity: 5.42% <BR>Price to Book: 1.84 <BR><BR>Contact Details:<BR>Address: Mayfair 1-8-303-34, Sardar Patel Road Secunderabad Andhra Pradesh : 500003 <BR>Tel: 91-40-27849700/27844557 <BR>Email: info@godavaridrugs.com <BR>Website: http://www.godavaridrugs.com

Are Godavari Drugs Ltd latest results good or bad?

Godavari Drugs Ltd's latest Q4 FY26 results show strong short-term growth with a 69.66% increase in net profit and a 49.50% rise in revenue, but concerns arise from a declining operating margin and low return on equity, indicating potential long-term challenges. Overall, the results are good short-term but raise questions about sustainability.

Godavari Drugs Ltd's latest results for Q4 FY26 show a mixed picture. On the positive side, the company achieved a net profit of ₹1.29 crores, which is a significant increase of 69.66% compared to the previous quarter. Additionally, revenue grew impressively by 49.50% quarter-on-quarter, reaching ₹33.16 crores, marking the highest quarterly sales in the company's history.<BR><BR>However, there are notable concerns as well. The operating margin decreased to 8.84%, down from 11.14% in the previous quarter, indicating that the revenue growth came at the expense of operational efficiency. Furthermore, the return on equity (ROE) stands at a modest 8.82%, which is below industry standards, reflecting challenges in capital efficiency.<BR><BR>Overall, while the quarterly performance shows strong short-term momentum, the company's long-term fundamentals remain weak, with a negative five-year sales CAGR of 2.92% and ongoing operational challenges. Thus, the results can be seen as good in the short term but concerning in the context of long-term sustainability. Investors should weigh these factors carefully.

How has been the historical performance of Godavari Drugs?

Godavari Drugs has shown a declining trend in net sales and profits over the past two years, with net sales dropping from 159.62 Cr in Mar'23 to 113.35 Cr in Mar'25, while total assets and liabilities have increased, indicating rising debt levels. Operating profit margins improved slightly, but overall financial performance reflects challenges in the market.

Answer:<BR>The historical performance of Godavari Drugs shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Godavari Drugs reported net sales of 113.35 Cr in Mar'25, a decline from 156.71 Cr in Mar'24 and 159.62 Cr in Mar'23, indicating a downward trend in revenue. The total operating income followed a similar pattern, decreasing from 156.71 Cr in Mar'24 to 113.35 Cr in Mar'25. Raw material costs also decreased to 85.24 Cr in Mar'25 from 121.95 Cr in Mar'24, while total expenditure fell to 101.52 Cr in Mar'25 from 143.41 Cr in Mar'24. Operating profit, excluding other income, was 11.83 Cr in Mar'25, slightly lower than 13.30 Cr in Mar'24, but the operating profit margin improved to 10.44%. Profit before tax decreased to 5.63 Cr in Mar'25 from 6.92 Cr in Mar'24, and profit after tax also fell to 4.38 Cr from 5.55 Cr. The company's total assets increased to 143.08 Cr in Mar'25 from 134.75 Cr in Mar'24, while total liabilities rose to 143.08 Cr from 134.75 Cr, indicating a growing debt level. Cash flow from operating activities decreased to 11.00 Cr in Mar'25 from 18.00 Cr in Mar'24, while cash flow from investing activities worsened to -19.00 Cr. Overall, Godavari Drugs has experienced a decline in sales and profits, alongside an increase in total assets and liabilities, reflecting a challenging financial environment.

Is Godavari Drugs overvalued or undervalued?

As of September 18, 2025, Godavari Drugs is considered very attractive and undervalued, with a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%, significantly lower than peers like Sun Pharma and Divi's Lab, while also showing strong long-term growth potential despite recent underperformance against the Sensex.

As of 18 September 2025, the valuation grade for Godavari Drugs has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios include a PE ratio of 16.95, an EV to EBITDA of 10.77, and a ROCE of 11.66%. <BR><BR>In comparison to its peers, Godavari Drugs stands out with a much lower PE ratio than Sun Pharma (34.46) and Divi's Lab (70.44), both of which are classified as expensive. Additionally, Godavari's PEG ratio is notably at 0.00, suggesting strong growth potential relative to its price. While the stock has underperformed the Sensex over the past year, its recent 5-year return of 136.84% compared to the Sensex's 113.70% highlights its long-term value proposition.

What is the technical trend for Godavari Drugs?

As of May 30, 2025, Godavari Drugs shows a mildly bearish trend, influenced by daily moving averages and monthly indicators, despite mixed signals from weekly MACD and KST.

As of 30 May 2025, the technical trend for Godavari Drugs has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, creating a mixed signal. The monthly MACD and Bollinger Bands are bearish, which adds to the overall bearish sentiment. The RSI shows no signal in both weekly and monthly time frames, indicating a lack of momentum. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly indicators.

Who are the top shareholders of the Godavari Drugs?

The top shareholders of Godavari Drugs include promoter Sushma Kakani with 15.34%, Highcrestt Global Company Ltd as the largest public shareholder at 2.66%, and individual investors holding a combined 39.93%. There are currently no mutual funds or foreign institutional investors in the company.

The top shareholders of Godavari Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sushma Kakani, with a stake of 15.34%. Additionally, Highcrestt Global Company Ltd is the highest public shareholder, owning 2.66% of the company. Individual investors collectively hold 39.93% of the shares. Notably, there are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

When is the next results date for Godavari Drugs?

No Upcoming Board Meetings

Has Godavari Drugs declared dividend?

No Dividend History Available